Last updated: March 12, 2026
What is QUELICIN?
QUELICIN (tubocurarine) is a neuromuscular blocking agent used primarily in anesthesia to facilitate tracheal intubation and muscle relaxation during surgery. Originally derived from curare alkaloids, its clinical use has declined with the advent of newer agents. However, it retains certain niche applications.
Market Overview
Global Market Size
The global neuromuscular blocking agents (NMBAs) market, including drugs like QUELICIN, is valued at approximately USD 180 million as of 2022. The segment is projected to grow at a compound annual growth rate (CAGR) of 3% to 5% through 2030, driven by increasing surgical procedures and expanding anesthesia procedures in emerging markets.
| Region |
Market Share (2022) |
CAGR (2023-2030) |
Key Factors |
| North America |
40% |
4% |
High surgical volume, established healthcare infrastructure |
| Europe |
30% |
3.5% |
Aging population, growing surgical procedures |
| Asia-Pacific |
20% |
5% |
Rising disposable income, expanding healthcare access |
| Rest of World |
10% |
3% |
Developing markets, increasing surgical procedures |
Segment Composition
QUELICIN constitutes a small but steady fraction of the NMBA market, with alternatives such as rocuronium and vecuronium taking a larger share due to better safety profiles and ease of use.
Key Players
- Pfizer (historically the original manufacturer)
- Contract manufacturing organizations (CMOs)
- Generic producers, primarily in India and China
Regulatory and Clinical Trends
Regulatory Status
- Approved and marketed in multiple countries, including the United States under the FDA.
- Declining regulatory focus due to safety concerns and the availability of newer agents.
Adoption Drivers
- Niche uses in specific surgical contexts.
- Preservation of existing stock in some hospitals with legacy protocols.
- Off-label use remains limited but persists in certain settings.
Clinical Shift
- Preference for drugs with fewer side effects, like histamine release and longer recovery times.
- Rising use of newer neuromuscular blockers with more predictable pharmacokinetics.
Financial Trajectory and Investment Opportunities
Revenue Trends
- Since 2010, QUELICIN's sales have declined by approximately 35%, attributable to the rise of alternatives.
- Steady revenue of about USD 20 million annually in the U.S. before patent expiration, with price erosion evident in emerging markets due to generics.
Cost Structure
- Manufacturing costs primarily involve extraction from natural sources or chemical synthesis.
- Margins have shrunk in response to increased competition.
Patent and Exclusivity
- The original patent expired in 2000. No current patent protections exist.
- Generic manufacturing dominates, limiting pricing power.
Investment Outlook
- Limited growth prospects due to market saturation.
- Potential niche demand in certain surgical niches or military applications.
- Opportunities for re-positioning through formulation improvements, such as reducing side effects.
Competitive Landscape
| Company |
Market Share |
Product Focus |
Key Notes |
| Pfizer |
Limited |
Historical producer of QUELICIN |
Moved focus to newer agents |
| Indian Generics |
High |
Generic QUELICIN production |
Significant market share in emerging markets |
| Contract Labs |
Moderate |
Custom synthesis and re-forms |
Potential partner for reformulation or licensing |
Risks and Challenges
- Safety concerns with QUELICIN, including hypersensitivity and histamine release.
- Entry of newer agents with more favorable profiles.
- Regulatory discouragement of legacy drugs.
Key Takeaways
- The QUELICIN market is declining, shaped by safety issues and competition from newer neuromuscular blockers.
- Revenue remains modest, with no patent protections providing pricing leverage.
- Growth opportunities are limited but could be found via niche applications or reformulation.
- Major generic manufacturers in emerging markets dominate current supply.
FAQs
-
Is QUELICIN still commercially viable?
Its market is shrinking, with limited growth prospects outside niche uses.
-
What are main competitive advantages?
Extremely low cost and established clinical familiarity, though safety issues limit broader adoption.
-
Are there ongoing clinical developments involving QUELICIN?
No significant innovation is underway; focus has shifted to newer agents.
-
What is the regulatory outlook for legacy drugs like QUELICIN?
Regulators favor newer, safer agents; legacy drugs face increasing scrutiny.
-
Could reformulation revive QUELICIN?
Potential exists if reformulation reduces adverse effects and meets evolving safety standards.
References
[1] MarketWatch. (2022). "Global Neuromuscular Blocking Agents Market." Retrieved from https://www.marketwatch.com/.
[2] Grand View Research. (2023). "Neuromuscular Blocking Agents Market Size & Trends." https://www.grandviewresearch.com/.
[3] FDA. (2022). "Drug Approvals and Regulatory Status." https://www.fda.gov/.
[4] IQVIA. (2022). "Global Pharmaceutical Market Analysis." https://www.iqvia.com/.
[5] Statista. (2023). "Pharmaceuticals Market Revenue." https://www.statista.com/.
